Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)

Bionorica

Status and phase

Completed

Phase 3

Conditions

Urinary Tract Infection

Treatments

Drug: Canephron® N

Study type

Interventional

Funder types

Industry

Identifiers

NCT01478620

2011-000838-11 (EudraCT Number)

CanUTI2

Details and patient eligibility

About

The objective of the study is to assess safety and impact of a non-antibiotic therapy approach with Canephron® N in the management strategy of uncomplicated lower urinary tract infections (UTIs).

Full description

250 patients total 7-day treatment period with Canephron® N (2 tablets three times a day) and a follow-up period until Day 37. A total of three visits are planned on Day 0 (screening, start of study treatment), Day 7 (end of study treatment) and Day 37 (end of study visit).

Additional visits can be performed anytime between Day 1 and Day 37 if deemed necessary by the investigator. In case the patients experience consistent or worsening of symptoms they may be offered antibiotic therapy at the discretion of the investigator at any time. In this case Canephron® N intake will be stopped.

At least 50% of the patients, i.e. 125 subjects, should have received a 7-day treatment with Canephron® N. If less subjects are available recruitment of subjects will be continued until the required number of 125 subjects is reached.

Due to withdrawal of study in Russia total study population was reduced to 125 patients.

Enrollment

125 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

Female outpatients aged 18-65 years (both inclusive).
Patients suffering of symptoms of uncomplicated lower urinary infection at screening. Patients must have a total sum score of at least six for the symptoms dysuria, frequency and urgency.
Development of symptoms within a maximum of 6 days before screening.
Willing to refrain from consuming prohibited concomitant medications and products.
Non-lactating female patients, who are surgically sterile (have had a documented bilateral oophorectomy and/or hysterectomy) or postmenopausal (cessation of menses for more than 1 year), or patients of childbearing potential with a negative pregnancy test at screening willing to use effective contraception methods (intrauterine device [IUD], hormonal contraceptives) during the study.

Main Exclusion Criteria:

Any signs evoking complicated UTI, pyelonephritis and/or concomitant vulvo-vaginitis
Any conditions that may lead to complicated infections (that is, renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, etc).
Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy.
Current signs or symptoms of severe, progressive or uncontrolled life-threatening systemic disease i.e. renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
Other acute infection (except UTI) requiring antibiotic treatment.
Patients receiving treatment for presumed or proven urinary tract infection within 4 weeks prior to study entry.
Antibiotic, immunosuppressive or immunostimulant (incl. vaccines) therapy within 4 weeks prior to study entry.
Patients with known history of anatomical genitourinary (GU) anomalies or GU surgery within 6 months prior to study entry.
Patients with known clinically significant abnormalities in screening physical examination, laboratory tests or vital signs.
Peptic ulcers and hypersensitivity and/or idiosyncrasy to centaury herb, lovage root, rosemary leaves or one of the other ingredients of the investigational medicinal product.
Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, galactose intolerance or lactase deficiency.
Patients with a history of severe drug allergy or hypersensitivity.
Known Human Immunodeficiency Virus (HIV)-seropositivity.